Milestone Pharmaceuticals Faces Low Stock, Seeks Profitability While Building Canadian Cardio Drugs
Milestone Pharmaceuticals, a Canadian firm on Nasdaq, struggles with a $0.695 stock price and negative P/E, yet pursues clinically‑validated cardiovascular drugs.
- MILESTONE PHARMACEUTICALS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read